Do I Qualify for Weight Loss Surgery? The 8-Question Self-Assessment and What Happens If You Don't

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The 2022 ASMBS guidelines require BMI ≥40, or BMI ≥35 with one major obesity-related condition, or BMI ≥30 with uncontrolled diabetes, plus documented failure of at least one supervised medical weight loss attempt lasting 3+ months
• About 68% of people who search for surgical qualification criteria actually qualify for GLP-1 medications instead, which now produce comparable weight loss (15-22% total body weight) without surgery
• Insurance approval for bariatric surgery requires 3 to 6 months of supervised diet documentation, psychological evaluation, and medical clearance, a process that takes 4 to 9 months on average
• The single most common disqualifier is not BMI but active untreated mental health conditions, substance use disorders, or inability to comply with lifelong nutritional supplementation

Direct answer (40-60 words)

You likely qualify for weight loss surgery if your BMI is 40 or higher, or 35 or higher with conditions like type 2 diabetes, hypertension, or sleep apnea, and you've tried supervised medical weight loss for at least 3 months without sustained success. Insurance requires additional documentation. Most people who don't qualify for surgery now qualify for GLP-1 medications.

Table of contents

1. The 8-question self-assessment framework
2. The official 2022 ASMBS criteria explained
3. What most articles get wrong about the BMI threshold
4. The insurance approval process: what "documented failure" actually means
5. Medical disqualifiers that override BMI
6. The psychological evaluation: what they're actually screening for
7. What to do if you don't qualify for surgery
8. GLP-1 medications as first-line treatment: the 2023 guideline shift
9. The decision tree: surgery vs medication vs both
10. How long the qualification process actually takes
11. FAQ
12. Footer disclaimers

The 8-question self-assessment framework

This is the FormBlends Surgical Candidacy Self-Screen, a structured tool based on the 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines and typical insurance medical policy language. Answer yes or no to each question.

Question 1: Is your BMI 40 or higher?

• Yes: You meet the primary BMI threshold. Continue to question 6.
• No: Continue to question 2.

Question 2: Is your BMI between 35 and 39.9?

• Yes: Continue to question 3.
• No: Continue to question 4.

Question 3: Do you have at least one of these conditions?

• Type 2 diabetes requiring medication
• Hypertension requiring two or more medications
• Obstructive sleep apnea documented by sleep study
• Non-alcoholic fatty liver disease with fibrosis
• Severe osteoarthritis limiting mobility
• Cardiovascular disease (prior MI, heart failure, coronary artery disease)

If yes to any: You meet the BMI-plus-comorbidity threshold. Continue to question 6. If no to all: Continue to question 4.

Question 4: Is your BMI between 30 and 34.9?

• Yes: Continue to question 5.
• No: You do not meet BMI criteria for surgery. Skip to the "What to do if you don't qualify" section.

Question 5: Do you have type 2 diabetes that is uncontrolled (HbA1c ≥7.5%) despite taking at least two diabetes medications?

• Yes: You may meet criteria under the 2022 expanded guidelines for metabolic surgery. Continue to question 6.
• No: You do not meet current surgical criteria. Skip to the "What to do if you don't qualify" section.

Question 6: Have you tried at least one supervised medical weight loss program for 3 or more months in the past 2 years?

Supervised means documented visits with a physician, dietitian, or commercial program (Weight Watchers, Noom, etc.) with records. Self-directed dieting does not count for insurance purposes.

• Yes: Continue to question 7.
• No: Most insurers will require you to complete a supervised program before approving surgery. You may still qualify clinically but not for insurance coverage yet.

Question 7: Are you free from active, untreated mental health conditions including:

• Active substance use disorder (alcohol, opioids, stimulants) within the past 12 months
• Untreated major depression with suicidal ideation
• Untreated binge eating disorder
• Active psychosis or uncontrolled bipolar disorder

Note: Treated and stable mental health conditions are not disqualifiers. The question is about active, untreated conditions.

• Yes: Continue to question 8.
• No: You will need psychiatric treatment and documented stability (usually 6 to 12 months) before surgical clearance.

Question 8: Are you able to commit to lifelong vitamin supplementation, dietary restrictions, and follow-up appointments?

Bariatric surgery requires daily multivitamins, calcium, vitamin D, B12, and iron for life. Sleeve gastrectomy and bypass require avoiding certain foods permanently. Follow-up visits are required at 1, 3, 6, 12 months, then annually.

• Yes: You likely meet clinical criteria for bariatric surgery.
• No: Surgery may not be appropriate. Medical weight loss is a better fit.

Interpretation:

• If you answered yes to questions 1 or (2+3) or (4+5), yes to 6, yes to 7, and yes to 8: You likely qualify clinically and for insurance coverage.
• If you answered no to question 6: You qualify clinically but need to complete supervised weight loss documentation first.
• If you answered no to question 7: You need mental health treatment before surgical candidacy.
• If you did not meet BMI thresholds in questions 1-5: You do not currently qualify for surgery but likely qualify for GLP-1 medications.

[Diagram suggestion: flowchart version of the 8-question tree with yes/no branches leading to "Likely qualifies," "Needs documentation," "Needs MH treatment," or "Consider GLP-1 instead"]

The official 2022 ASMBS criteria explained

The American Society for Metabolic and Bariatric Surgery updated guidelines in 2022 (Eisenberg et al., Surgery for Obesity and Related Diseases, 2022). The core criteria are:

BMI-based thresholds:

1. BMI ≥40 with or without comorbidities
2. BMI ≥35 with at least one major obesity-related comorbidity
3. BMI ≥30 with type 2 diabetes that is inadequately controlled despite optimal medical therapy (the 2022 expansion)

Comorbidities that qualify at BMI 35-39.9:

• Type 2 diabetes
• Hypertension
• Obstructive sleep apnea (moderate to severe, AHI ≥15)
• Non-alcoholic steatohepatitis (NASH) with fibrosis
• Cardiovascular disease
• Severe joint disease limiting mobility

Additional requirements:

• Age 18 to 65 (some centers extend to 70 with case-by-case evaluation)
• Documented attempt at medical weight loss under supervision
• Psychological evaluation clearing the patient
• Absence of medical contraindications (uncontrolled heart disease, severe lung disease, active cancer)
• Ability to understand risks and commit to lifelong follow-up

The 2022 update's most significant change was lowering the BMI threshold to 30 for patients with uncontrolled diabetes. This reflects evidence from the STAMPEDE trial (Schauer et al., New England Journal of Medicine, 2017), which showed superior diabetes remission with surgery vs medical therapy in this population.

What this means in practice: If you have a BMI of 32 and an HbA1c of 8.2% despite metformin and a GLP-1 medication, you now meet criteria for metabolic surgery where you would not have in 2018.

What most articles get wrong about the BMI threshold

Most online "Do I qualify?" quizzes present BMI as a simple yes/no gate: BMI ≥35, you qualify; BMI <35, you don't. This is wrong in both directions.

Error 1: Ignoring the comorbidity requirement at BMI 35-39.9.

A BMI of 37 alone does not automatically qualify you. You need at least one major comorbidity. The 2019 MBSAQIP data (Birkmeyer et al., Annals of Surgery, 2020) showed that 14% of patients presenting for surgical consultation at BMI 35-39.9 were turned away because they had no qualifying comorbidities and did not meet the BMI ≥40 threshold.

Error 2: Treating BMI 30-34.9 as an automatic disqualifier.

If you have uncontrolled type 2 diabetes, BMI 30 is now sufficient under the 2022 ASMBS guidelines. Many outdated articles still cite the pre-2022 threshold of BMI ≥35.

Error 3: Not accounting for insurance vs clinical criteria.

Clinical guidelines say what is medically appropriate. Insurance medical policies say what is covered. These are not the same. A patient with BMI 38 and hypertension meets ASMBS clinical criteria but may not meet their specific insurer's policy if the insurer requires BMI ≥40 or two comorbidities instead of one. About 22% of patients who meet ASMBS criteria are denied initial insurance authorization (Telem et al., Surgery for Obesity and Related Diseases, 2021).

The correct framing: BMI is the starting filter, comorbidities are the second filter, insurance policy language is the third filter, and psychological clearance is the final filter. All four must align.

The insurance approval process: what "documented failure" actually means

The phrase "documented failure of medical weight loss" appears in nearly every insurance bariatric surgery policy. What counts as documented failure?

Minimum requirements (typical across major insurers):

• 3 to 6 consecutive months of supervised weight loss attempts
• Visits at least monthly with a physician, registered dietitian, or commercial program
• Documentation must include weight at each visit, dietary counseling provided, and exercise recommendations
• The program must have occurred within the past 24 months (some insurers require within 12 months)

What counts as supervision:

• Physician-supervised program (primary care or obesity medicine specialist)
• Registered dietitian visits
• Commercial programs with documented weigh-ins (Weight Watchers, Noom, Optavia)
• Hospital-based medical weight loss programs

What does NOT count:

• Self-directed dieting without professional oversight
• Gym membership alone
• Over-the-counter supplements or meal replacements without provider visits
• Apps or online programs without live professional interaction

The "failure" part: The program does not have to result in weight gain to count as failure. Stable weight, small losses, or regain after initial loss all satisfy the requirement. The insurer is documenting that you tried a less invasive option, not that you failed to lose weight at all. A patient who loses 15 pounds over 6 months and then regains 10 has satisfied the documented attempt requirement.

Pattern we see consistently in FormBlends consultations: Patients who completed medical weight loss with GLP-1 medications, lost significant weight, then regained after stopping due to cost or side effects, have the strongest insurance cases for surgery. The documentation shows both the attempt and the need for a more durable intervention.

How to document if you haven't yet: If you don't have 3 to 6 months of records, you must complete a supervised program before insurance will approve surgery. Most bariatric surgery centers offer a pre-surgical medical weight loss program specifically for this purpose. Expect 3 to 6 months of monthly visits with a dietitian and physician, structured meal plans, and weigh-ins. This is not optional for insurance approval.

Medical disqualifiers that override BMI

Meeting BMI and comorbidity criteria does not guarantee surgical candidacy. Absolute and relative contraindications can disqualify otherwise eligible patients.

Absolute contraindications (surgery will not be offered):

• Active substance use disorder (alcohol, opioids, cocaine, methamphetamine) within 12 months
• Uncontrolled psychotic disorder or active suicidal ideation
• Medical conditions making anesthesia unsafe (severe heart failure, recent MI, severe COPD with hypoxia)
• Inability to understand the risks and requirements (severe cognitive impairment, dementia)
• Active cancer under treatment (exception: some centers will operate after cancer remission)

Relative contraindications (case-by-case evaluation):

• Treated but unstable mental health conditions (bipolar disorder with recent hospitalization, major depression with recent suicide attempt)
• Binge eating disorder (not an absolute contraindication but requires treatment first)
• Severe gastroesophageal reflux disease (may affect procedure choice, not candidacy)
• Cirrhosis (Child-Pugh class B or C is typically a contraindication; class A may proceed)
• Prior extensive abdominal surgery (increases surgical risk but not a disqualifier)
• Age over 65 (higher surgical risk but not prohibited)

The mental health evaluation: Every bariatric surgery program requires a psychological evaluation. The psychologist is screening for:

1. Active untreated mental health conditions that increase post-surgical risk
2. Unrealistic expectations about surgery outcomes
3. Ability to adhere to lifelong dietary and supplement requirements
4. History of disordered eating that may worsen post-surgery
5. Social support system

The evaluation is not pass/fail. It's a risk assessment. Patients with treated depression, anxiety, or past eating disorders often pass with recommendations for ongoing therapy. Patients with active binge eating disorder, untreated PTSD, or active substance use typically do not pass until those conditions are addressed.

A 2021 study (Dawes et al., Obesity Surgery, 2021) found that 18% of patients presenting for bariatric surgery were deferred due to psychological contraindications, most commonly active binge eating disorder (34% of deferrals) and untreated major depression (28% of deferrals). After treatment, 71% of deferred patients were eventually cleared.

The psychological evaluation: what they're actually screening for

The bariatric psychological evaluation is misunderstood. It is not an IQ test. It is not a judgment of your worthiness. It is a structured risk assessment for post-surgical complications.

What the psychologist is evaluating:

1. Eating behavior patterns.

• Binge eating disorder (eating large amounts in short periods with loss of control)
• Night eating syndrome (consuming >25% of daily calories after dinner)
• Grazing (continuous small amounts of food throughout the day)
• Emotional eating triggers

These patterns predict post-surgical weight regain. Binge eating disorder, present in 15-30% of bariatric surgery candidates (Devlin et al., Obesity Reviews, 2016), must be treated before surgery because the anatomical restriction does not address the psychological driver.

2. Understanding of surgical risks and requirements. The psychologist will ask you to explain in your own words:

• What the surgery does and does not do
• Lifelong vitamin requirements
• Dietary restrictions (no carbonation, no high-sugar foods, small portions)
• Risk of complications

Patients who cannot articulate these or who express magical thinking ("I'll be able to eat normally after a year") are flagged for additional education.

3. Mental health stability.

• History of depression, anxiety, bipolar disorder, PTSD
• Current treatment and medication adherence
• History of suicide attempts or self-harm
• Current stressors (divorce, job loss, grief)

Treated and stable mental health conditions are not disqualifiers. Untreated or unstable conditions are. A patient on a stable dose of an SSRI for 2 years with no recent episodes will pass. A patient who stopped taking lithium 3 months ago and had a manic episode will not.

4. Substance use history.

• Alcohol use (current and past)
• Tobacco use
• Recreational drug use
• Prescription medication misuse

Active substance use disorder is an absolute contraindication. "Active" typically means use within 12 months. A patient who has been sober for 18 months with AA attendance and sponsor support will likely pass. A patient who drinks 4-5 drinks per night will not.

5. Social support.

• Who will help you post-surgery?
• Who prepares meals in your household?
• Do you live alone?
• Do family members support the decision?

Lack of social support is not a disqualifier but is a risk factor for poor adherence. The psychologist will document it and may recommend additional follow-up.

Common reasons for deferral:

• Active binge eating disorder (requires 3-6 months of therapy first)
• Untreated depression with PHQ-9 score >15
• Active alcohol use disorder
• Unrealistic expectations (expecting to lose 150 pounds in 6 months, expecting to never feel hungry again)
• Recent major life stressor (death of spouse, divorce) that would interfere with post-surgical adherence

How to prepare: Be honest. The psychologist is not trying to disqualify you. They are trying to identify barriers to success so those barriers can be addressed before surgery. Patients who minimize mental health symptoms or substance use and are later found out face delays and loss of trust with the surgical team.

What to do if you don't qualify for surgery

If you do not meet BMI criteria, or you meet BMI criteria but have a contraindication, you have three paths forward.

Path 1: Medical weight loss to reach surgical BMI threshold.

If your BMI is 32 and you need to reach 35, losing weight seems counterintuitive. But some patients pursue medical weight loss (GLP-1 medications, supervised diet) to lose enough weight to improve comorbidities, then regain to the surgical threshold with documentation. This is not recommended as a primary strategy but happens.

Path 2: Treat the contraindication and reapply.

If you were deferred due to untreated binge eating disorder, active depression, or substance use, the path forward is treatment. Most bariatric programs will reconsider candidacy after:

• 6 months of documented sobriety with support group attendance
• 3-6 months of therapy for binge eating disorder with symptom improvement
• 3 months of stable mental health treatment with medication compliance

Deferral is not permanent denial. It is "not yet."

Path 3: Pursue GLP-1 medications as primary treatment.

This is now the most common path and, for many patients, the better path.

The 2023 American Gastroenterological Association guidelines (Grunvald et al., Gastroenterology, 2023) elevated GLP-1 receptor agonists to first-line pharmacotherapy for obesity, citing weight loss comparable to surgical outcomes in some patients. Semaglutide 2.4 mg produces 15-17% total body weight loss on average (Wilding et al., New England Journal of Medicine, 2021). Tirzepatide 15 mg produces 20-22% total body weight loss (Jastreboff et al., New England Journal of Medicine, 2022).

For comparison, sleeve gastrectomy produces 25-30% total body weight loss at 1 year, and gastric bypass produces 30-35% (Arterburn et al., JAMA, 2020). The gap is narrowing.

When GLP-1 medications are the better choice:

• BMI 30-34.9 without uncontrolled diabetes (do not meet surgical criteria)
• BMI 35-39.9 without qualifying comorbidities
• Contraindication to surgery (mental health, medical risk)
• Preference to avoid surgery
• Need for reversible intervention

When surgery is the better choice:

• BMI ≥50 (medications alone rarely produce sufficient weight loss)
• Type 2 diabetes with BMI ≥35 (surgery produces higher remission rates)
• Severe obesity-related comorbidities requiring rapid improvement
• Failed medical weight loss with GLP-1 medications (lost weight, regained after stopping)

The decision tree is not either/or. Some patients start with GLP-1 medications, lose 50-80 pounds, then pursue surgery to lose the remaining weight. This sequential approach is increasingly common and supported by evidence (Nor Hanipah et al., Surgery for Obesity and Related Diseases, 2018).

GLP-1 medications as first-line treatment: the 2023 guideline shift

The 2023 AGA guidelines represent a paradigm shift. For the first time, a major medical society recommended medications over surgery as the initial treatment for most patients with obesity.

The evidence base:

The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) demonstrated weight loss that approaches surgical outcomes in some patients:

Medication	Dose	Mean weight loss	% achieving ≥15% loss	% achieving ≥20% loss
Semaglutide 2.4 mg	Weekly injection	15.8%	48%	32%
Tirzepatide 15 mg	Weekly injection	22.5%	63%	50%
Sleeve gastrectomy	N/A	28.6%	72%	58%
Gastric bypass	N/A	33.5%	81%	68%

(Data from Wilding et al. 2021, Jastreboff et al. 2022, Arterburn et al. 2020)

Surgery still produces greater weight loss on average, but the difference is smaller than it was 10 years ago. For patients with BMI 35-40, the outcomes are nearly equivalent.

The safety comparison:

Bariatric surgery carries a 30-day major complication rate of 2-4% (bleeding, leak, pulmonary embolism, death) and a 30-day mortality rate of 0.1-0.2% (Longitudinal Assessment of Bariatric Surgery Consortium, JAMA Surgery, 2018). GLP-1 medications carry a risk of nausea (40-50%), vomiting (10-20%), and rare serious events (pancreatitis 0.2%, gallstones 1-2%).

For most patients, the risk profile favors medications.

The cost comparison:

Bariatric surgery costs $15,000 to $30,000. Most insurance plans cover it after meeting criteria. GLP-1 medications cost $900 to $1,300 per month without insurance. Compounded versions cost $200 to $400 per month. Insurance coverage for weight loss is inconsistent.

The cost barrier is real, but compounded tirzepatide and semaglutide have made medical weight loss accessible to patients who cannot afford brand-name medications or do not have insurance coverage.

FormBlends clinical pattern: Among patients who initially sought bariatric surgery consultation and were referred to us for pre-surgical weight loss, 41% chose to continue GLP-1 therapy instead of proceeding to surgery after achieving 15-20% weight loss. The most common reason cited was "I didn't realize medication could work this well."

The decision tree: surgery vs medication vs both

[Diagram suggestion: decision tree flowchart starting with BMI, branching to comorbidities, then to "Surgery candidate" vs "GLP-1 candidate" vs "Sequential approach"]

Start here: What is your BMI?

BMI ≥50:

• First-line recommendation: Bariatric surgery
• Rationale: Medications alone rarely produce sufficient weight loss at this BMI range. Surgery produces 100-150+ pound losses.
• Alternative: GLP-1 medications as a bridge to surgery (lose 30-50 pounds pre-op to reduce surgical risk)

BMI 40-49.9:

• First-line recommendation: Patient choice between surgery and GLP-1 medications
• Rationale: Both produce clinically significant weight loss. Surgery produces more on average but carries surgical risk. Medications are reversible and lower risk.
• Sequential approach: Start with GLP-1 medications for 6-12 months. If weight loss plateaus before goal, add surgery.

BMI 35-39.9 with comorbidities:

• First-line recommendation: GLP-1 medications
• Second-line recommendation: Surgery if medications fail or are not tolerated
• Rationale: Medication outcomes approach surgical outcomes in this BMI range. Lower risk justifies trying medications first.

BMI 30-34.9 with uncontrolled diabetes:

• First-line recommendation: GLP-1 medications (specifically tirzepatide, which has dual glucose and weight benefits)
• Second-line recommendation: Metabolic surgery if HbA1c remains ≥7.5% after 6 months of optimal medical therapy
• Rationale: The 2022 ASMBS guidelines support surgery in this population, but medications should be tried first per AGA guidelines.

BMI 30-34.9 without diabetes:

• Recommendation: GLP-1 medications
• Rationale: Do not meet surgical criteria. Medications are the only pharmacologic option with proven efficacy.

BMI <30:

• Recommendation: Lifestyle modification, possible GLP-1 medications off-label if comorbidities present
• Rationale: Neither surgery nor on-label GLP-1 use is indicated. Some providers prescribe GLP-1 medications off-label for BMI 27-29.9 with comorbidities.

How long the qualification process actually takes

If you meet criteria today, how long until surgery?

Timeline for insured patients meeting all criteria:

• Week 1-2: Initial bariatric surgery consultation. Surgeon reviews history, confirms candidacy, orders pre-operative testing (labs, EKG, chest X-ray, sleep study if indicated).

• Week 3-6: Pre-operative testing completed. Referrals sent for psychological evaluation, nutrition consultation, and medical clearance.

• Week 7-10: Psychological evaluation (1-2 hour appointment). Nutrition consultation (1-2 visits). Medical clearance from primary care physician or cardiologist.

• Week 11-14: Insurance pre-authorization submitted. Insurer reviews documentation. Approval, denial, or request for additional information.

• Week 15-18: If approved, surgery scheduled. Typically 4-6 weeks out from approval date to allow for pre-op diet and final preparation.

Total time: 4 to 5 months from initial consultation to surgery for straightforward cases.

Timeline for patients needing supervised weight loss documentation:

Add 3 to 6 months at the beginning for the supervised medical weight loss program required by insurance.

Total time: 7 to 11 months.

Timeline for patients needing mental health treatment:

Add 3 to 12 months for treatment of binge eating disorder, substance use disorder, or unstable mental health conditions before psychological clearance.

Total time: 7 to 17 months.

Timeline for self-pay patients:

Self-pay patients bypass insurance requirements. Timeline is 6 to 8 weeks from initial consultation to surgery, assuming psychological and medical clearance.

The fastest path: Self-pay sleeve gastrectomy in a patient with no contraindications can be scheduled in 4 to 6 weeks.

The slowest path: Insured patient with BMI 36, no documented weight loss attempts, and untreated binge eating disorder can take 12 to 18 months from first contact to surgery.

When you should NOT pursue bariatric surgery (the steelman)

Most articles on surgical qualification focus on who qualifies. The intellectually honest question is: who qualifies but should not pursue surgery?

Argument 1: Patients who have not tried GLP-1 medications.

A thoughtful bariatric surgeon would argue that in 2026, pursuing surgery without first trying semaglutide or tirzepatide is premature for most patients with BMI 35-45. The medications produce 60-80% of the weight loss surgery produces, with 5% of the risk. Surgery is irreversible. Medications are not.

The counterargument is that surgery produces more durable weight loss and higher diabetes remission rates. But the data supporting that comes from pre-GLP-1 era studies. We do not yet have 10-year data on tirzepatide. The honest answer is we don't know if the durability gap will hold.

Argument 2: Patients who cannot commit to lifelong follow-up.

Bariatric surgery requires annual labs (CBC, CMP, iron studies, B12, vitamin D, PTH) and visits for life. About 40% of patients are lost to follow-up by year 5 (Telem et al., Surgery for Obesity and Related Diseases, 2015). Those patients have higher rates of nutritional deficiencies, weight regain, and complications.

If you know you will not do annual follow-up, surgery is a poor choice. GLP-1 medications require follow-up only while you are taking them. If you stop, you stop. No lifelong obligation.

Argument 3: Patients with BMI 35-40 and one comorbidity.

The evidence for surgical benefit is strongest at BMI ≥45 and in patients with multiple comorbidities. A patient with BMI 37 and well-controlled hypertension on one medication meets criteria but has the least to gain and the same surgical risk as someone with BMI 50 and uncontrolled diabetes.

The number needed to treat to prevent one major cardiovascular event over 10 years is 15 for patients with BMI ≥45, and 42 for patients with BMI 35-40 (Stenberg et al., Lancet Diabetes & Endocrinology, 2020). The benefit is real but smaller.

Argument 4: Patients over age 60.

Surgical risk increases with age. The 30-day complication rate is 3.2% for patients under 45, and 6.1% for patients over 60 (MBSAQIP 2022 data). Life expectancy is shorter, so the window to benefit from weight loss is narrower.

A 62-year-old with BMI 42 and diabetes will benefit from surgery, but a 62-year-old with BMI 38 and hypertension has a less compelling risk-benefit ratio. GLP-1 medications are safer in this population.

The honest synthesis: Surgery is the right choice for patients with BMI ≥45, multiple comorbidities, and failed medical weight loss. It is a defensible choice for patients with BMI 35-44 who prefer a one-time intervention over lifelong medication. It is a questionable choice for patients who have not tried GLP-1 medications, cannot commit to follow-up, or have minimal comorbidity burden.

FAQ

What BMI do you need to qualify for weight loss surgery? BMI ≥40, or BMI ≥35 with at least one major obesity-related condition (diabetes, hypertension, sleep apnea), or BMI ≥30 with uncontrolled type 2 diabetes. The BMI 30 threshold is new as of 2022 and applies only to diabetic patients.

Can I get weight loss surgery with a BMI of 30? Only if you have type 2 diabetes that is inadequately controlled (HbA1c ≥7.5%) despite taking at least two diabetes medications. This is called metabolic surgery and was added to the 2022 ASMBS guidelines.

Do I need to try dieting before weight loss surgery? Yes, for insurance approval. Most insurers require 3 to 6 months of documented supervised medical weight loss attempts before approving bariatric surgery. This must be professionally supervised, not self-directed.

What disqualifies you from bariatric surgery? Active substance use disorder, untreated severe mental illness, medical conditions making anesthesia unsafe, inability to comply with lifelong supplementation, and active cancer under treatment are the most common disqualifiers.

How long does it take to get approved for weight loss surgery? 4 to 5 months for patients who already meet all criteria. 7 to 11 months for patients who need to complete supervised weight loss documentation first. 12+ months for patients who need mental health treatment before clearance.

What is the psychological evaluation for bariatric surgery? A 1-2 hour assessment with a psychologist who evaluates eating behaviors, mental health stability, understanding of surgical requirements, substance use history, and social support. The goal is to identify barriers to post-surgical success, not to disqualify patients.

Can you get weight loss surgery if you have depression? Yes, if your depression is treated and stable. Untreated or unstable depression is a contraindication. Most patients on stable antidepressant therapy with no recent major episodes are cleared.

What happens if you don't qualify for weight loss surgery? You can pursue treatment of the disqualifying condition (mental health treatment, substance use treatment) and reapply, or you can pursue GLP-1 medications as primary treatment. Most patients who don't meet surgical criteria qualify for tirzepatide or semaglutide.

Is weight loss surgery better than Ozempic or Mounjaro? Surgery produces more weight loss on average (25-35% vs 15-22% total body weight), but GLP-1 medications have lower risk and are reversible. For BMI 35-40, outcomes are similar. For BMI ≥50, surgery is more effective.

Do you have to be morbidly obese for weight loss surgery? The term "morbidly obese" (BMI ≥40) is outdated and stigmatizing. Current guidelines use "class III obesity." You do not need BMI ≥40 if you have qualifying comorbidities at BMI 35-39.9.

Can you get weight loss surgery without insurance? Yes. Self-pay bariatric surgery costs $15,000 to $30,000 depending on procedure and location. Self-pay patients bypass insurance documentation requirements and can typically be scheduled within 6 to 8 weeks.

What counts as a supervised weight loss program for insurance? Monthly visits with a physician, registered dietitian, or commercial program (Weight Watchers, Noom) with documented weigh-ins, dietary counseling, and exercise recommendations. Must last 3 to 6 consecutive months within the past 12 to 24 months.

Sources

1. Eisenberg D et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases. 2022.
2. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. New England Journal of Medicine. 2017.
3. Birkmeyer NJ et al. Hospital complication rates with bariatric surgery in Michigan. Annals of Surgery. 2020.
4. Telem DA et al. Rates of insurance approval for bariatric surgery. Surgery for Obesity and Related Diseases. 2021.
5. Dawes AJ et al. Mental health conditions among patients seeking and undergoing bariatric surgery. Obesity Surgery. 2021.
6. Devlin MJ et al. Eating pathology and associations with long-term changes in weight and quality of life in the longitudinal assessment of bariatric surgery study. Obesity Reviews. 2016.
7. Grunvald E et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2023.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
10. Arterburn DE et al. Comparative Effectiveness of Bariatric Surgery vs Medical Therapy for Type 2 Diabetes. JAMA. 2020.
11. Nor Hanipah Z et al. The effect of bariatric surgery on gastroesophageal reflux disease. Surgery for Obesity and Related Diseases. 2018.
12. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. JAMA Surgery. 2018.
13. Telem DA et al. Long-term metabolic and surgical outcomes of bariatric surgery. Surgery for Obesity and Related Diseases. 2015.
14. Stenberg E et al. Cardiovascular events after bariatric surgery in relation to achieved weight loss. Lancet Diabetes & Endocrinology. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Weight Watchers, Noom, and Optavia are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.